What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

In morning trades, Moderna stock rose nearly 4% to 28.22 ... support rapid response in a future influenza pandemic, and pave ...

Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...

Expert Outlook: Moderna Through The Eyes Of 19 Analysts December 10, 2024 — 10:00 am EST. ... Price Targets: Analysts set price targets as an estimate of a stock's future value.

Despite cost cuts, Moderna posted a second straight quarterly loss. It now sees 2024 sales ranging between $3 billion and $3.5 billion, down from its previous outlook of about $4 billion ...

Moderna is on its way to getting a third mRNA-based vaccine approved by the FDA if the regulatory agency likes the data released Monday for a combination flu-COVID shot.The company said the new ...

Shares of Moderna Inc. were plunging in early trading Monday, after the biotechnology company provided a downbeat revenue outlook and said it expects to burn more than $3 billion in cash in 2025.

Moderna’s new TV spot, “Welcome to the mRNAge," is here to let people know that messenger RNA vaccines are not just a one trick (COVID-19) pony.

Moderna Inc.’s third-quarter revenue fell by nearly a third and the pharmaceutical company cut its outlook, saying as part of its earnings report that supply constraints for its Covid-19 ...

Moderna Inc. shares moved lower Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter earnings and lowered full-year sales guidance by up to $3 billion.